Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grass-SPIRE safety in asthma and grass allergy
NCT02161107Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of grass-spire in seasonal allergic rhinitis (SAR) and asthma (3 arms), sponsored by NIOX Group. Primary endpoint: Number of subjects with adverse events at 15 weeks. Started Apr 2014; status: completed.
02
Drugs
grass-spire
03
Conditions
seasonal allergic rhinitis (SAR)asthma
Beyond the preview
Go deeper on NCT02161107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161107.